Solara Active

how big is Solara Active?

As of Jun 06, Solara Active Pharma Sciences Ltd has a market capitalization of 1,712.00 Cr, with recent net sales of 1,283.76 Cr and a net profit of 0.54 Cr over the last four quarters. The shareholder's funds are 933.91 Cr, and total assets are valued at 2,350.96 Cr as of Mar'24.

Market Cap: As of Jun 06, Solara Active Pharma Sciences Ltd has a market capitalization of 1,712.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 1,283.76 Cr, and the sum of Net Profit is 0.54 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the reporting period of Mar'24. The Shareholder's Funds amount to 933.91 Cr, and the Total Assets are valued at 2,350.96 Cr.

When is the next results date for Solara Active?

No Upcoming Board Meetings

Has Solara Active declared dividend?

Yes, Solara Active Pharma Sciences Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of August 18, 2021. However, the dividend yield is 0%, and total returns over various periods have shown mixed performance, including significant losses in some cases.

Solara Active Pharma Sciences Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 18 Aug 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -39.77%, the dividend return was 0%, resulting in a total return of -39.77%.<BR><BR>For the 1-year period, the price return was 11.99%, the dividend return was 0%, leading to a total return of 11.99%.<BR><BR>Over the 2-year period, the price return was 39.98%, the dividend return was 0%, culminating in a total return of 39.98%.<BR><BR>In the 3-year period, the price return was 25.28%, the dividend return was 0%, which resulted in a total return of 25.28%.<BR><BR>During the 4-year period, the price return was -71.6%, the dividend return was 0.18%, resulting in a total return of -71.42%.<BR><BR>For the 5-year period, the price return was -11.39%, the dividend return was 1.45%, leading to a total return of -9.94%.<BR><BR>Overall, while Solara Active has declared a dividend, the dividend yield remains at 0%, indicating that recent performance has not significantly benefited shareholders in terms of returns. The total returns show a mixed performance over various periods, with some periods reflecting substantial losses.

Who are the peers of the Solara Active?

Peers of Solara Active include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bajaj Healthcare, Jagsonpal Pharma, Hester Bios, and Bliss GVS Pharma. Solara Active has below average management risk and growth, with a 1-year return of 17.79%.

Peers: The peers of Solara Active are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bajaj Healthcare, Jagsonpal Pharma, Hester Bios, and Bliss GVS Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Bajaj Healthcare, while Average management risk is found at Jagsonpal Pharma, Hester Bios, and Bliss GVS Pharma. Below Average management risk is noted for Solara Active. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Solara Active, Bajaj Healthcare, Hester Bios, and Bliss GVS Pharma, and Good growth is noted at Jagsonpal Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Bliss GVS Pharma, Good for Torrent Pharma, Average for Bajaj Healthcare, and Below Average for Solara Active, Hester Bios, and Jagsonpal Pharma.<BR><BR>Return Snapshot: Bajaj Healthcare has the highest 1-year return at 85.57%, while Themis Medicare has the lowest at -34.24%. Solara Active's 1-year return is 17.79%, which is significantly lower than Bajaj Healthcare's but higher than Themis Medicare's. Additionally, the six-month return is negative for Solara Active, Hester Bios, and Themis Medicare.

Who are in the management team of Solara Active?

As of March 2023, the management team of Solara Active includes Jitesh Devendra and Poorvank Purohit as Managing Directors & CEOs, S Hariharan as Executive Director & CFO, and several independent and non-executive directors, including Aditya Puri as Chairman. The team is composed of a mix of executive and independent directors to ensure effective governance.

As of March 2023, the management team of Solara Active includes the following members:<BR><BR>1. Aditya Puri - Chairman & Non Executive Director<BR>2. Nirmal P Bhogilal - Independent Director<BR>3. Vineeta Rai - Independent Director<BR>4. RAJAGOPALAN RAMAKRISHNAN - Independent Non Executive Director<BR>5. Kausalya Santhanam - Independent Director<BR>6. ANKUR NAND THADANI - Non Executive Director<BR>7. Arun Kumar - Non Executive Director<BR>8. S Hariharan - Executive Director & CFO<BR>9. Jitesh Devendra - Managing Director & CEO<BR>10. Poorvank Purohit - Managing Director & CEO<BR>11. Rajendra Kumar Srivastava - Additional Director<BR>12. Rajiv Vijay Naba - Additional Director<BR><BR>This team comprises a mix of executive and non-executive directors, including independent directors, contributing to the governance and management of the company.

What does Solara Active do?

Solara Active Pharma Sciences Ltd manufactures and distributes active pharmaceutical ingredients (APIs) and reported net sales of 2,730 Cr and a net loss of 21 Cr for March 2025, with a market cap of INR 2,521 Cr. The company has a P/E ratio of 2,493.00 and a debt-equity ratio of 0.72.

Overview: <BR>Solara Active Pharma Sciences Ltd is engaged in the manufacturing and distribution of active pharmaceutical ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.<BR><BR>History: <BR>The company was incorporated on February 23, 2017. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 2,730 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -21 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 2,521 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 2,493.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.72 <BR>Return on Equity: 0.05% <BR>Price to Book: 2.29<BR><BR>Contact Details: <BR>Address: 201 Devavrata Sector 17 Vashi, Navi Mumbai Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27892924 <BR>Email: investors@solara.co.in <BR>Website: http://www.solara.co.in

Who are the top shareholders of the Solara Active?

The top shareholders of Solara Active include Devicam Capital LLP with 15.53%, individual investors with 23.07%, and 55 foreign institutional investors holding 14.63%. Notably, Spiracca Ventures LLP holds 7.72%, and 34.64% of promoter holdings are pledged.

The top shareholders of Solara Active include a mix of institutional and individual investors. The largest promoter is Devicam Capital LLP, holding 15.53%. Additionally, there are significant holdings from individual investors, who collectively own 23.07%. The company also has 55 foreign institutional investors (FIIs) with a combined holding of 14.63%. Among public shareholders, Spiracca Ventures LLP stands out with a holding of 7.72%. It's worth noting that a portion of the promoter holdings, specifically 34.6353%, is pledged.

Is Solara Active overvalued or undervalued?

As of November 7, 2025, Solara Active is considered overvalued due to its high PE ratio of 318.76, an EV to EBITDA of 38.62, and a PEG ratio of 3.13, all significantly higher than its peers, alongside a disappointing year-to-date return of -16.41%.

As of 7 November 2025, Solara Active's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently overvalued, primarily due to its exceptionally high PE ratio of 318.76, which is significantly higher than its peers. In comparison, Sun Pharma has a PE ratio of 35.17, while Cipla boasts a much lower PE of 22.33, highlighting the disparity in valuation.<BR><BR>Additionally, Solara's EV to EBITDA stands at 38.62, again placing it in a less favorable position compared to its peers like Dr. Reddy's Labs, which has an EV to EBITDA of 10.52. The PEG ratio of 3.13 further underscores the overvaluation, especially when compared to Cipla's PEG of 1.25. Recent stock performance has also been underwhelming, with a year-to-date return of -16.41% compared to a 6.50% gain in the Sensex, reinforcing the notion that Solara Active is currently overvalued in the market.

How has been the historical performance of Solara Active?

Solara Active's historical performance has shown significant fluctuations, with net sales declining from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25, but recent figures indicate a potential recovery in profitability and cash flow, with profit before tax and profit after tax turning positive in Mar'25 after previous losses. Total liabilities decreased, and cash flow from operating activities improved to 212.00 Cr in Mar'25.

Answer:<BR>The historical performance of Solara Active shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Solara Active's net sales have seen a decline from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25, with a notable drop from 1,443.81 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25. Operating profit (PBDIT) also experienced volatility, peaking at 414.64 Cr in Mar'21 before falling to 214.60 Cr in Mar'25, with a significant loss of -89.81 Cr in Mar'24. Profit before tax turned positive again in Mar'25 at 0.54 Cr after a series of losses, while profit after tax showed a recovery to 0.54 Cr from a substantial loss of -566.96 Cr in Mar'24. The company's total liabilities decreased from 2,820.72 Cr in Mar'23 to 2,231.84 Cr in Mar'25, indicating a reduction in debt levels. Cash flow from operating activities improved to 212.00 Cr in Mar'25 compared to 108.00 Cr in Mar'24, although the net cash outflow was -4.00 Cr in Mar'25. Overall, while Solara Active has faced challenges, recent figures suggest a potential recovery in profitability and cash flow.

Is Solara Active technically bullish or bearish?

As of December 4, 2025, Solara Active's trend is neutral with mixed signals, showing a mildly bearish stance on weekly and monthly MACD and Bollinger Bands, while daily moving averages and On-Balance Volume suggest slight bullishness.

As of 4 December 2025, the technical trend for Solara Active has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD remains bearish, while the monthly MACD is mildly bearish. The RSI shows no signal on both weekly and monthly time frames. Bollinger Bands indicate a mildly bearish trend on both weekly and monthly charts. Daily moving averages are mildly bullish, providing some support. The KST is bearish weekly and mildly bearish monthly, while Dow Theory shows a mildly bearish weekly stance with no trend monthly. However, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames, suggesting some accumulation. Overall, the mixed indicators reflect a neutral stance with a slight inclination towards bullishness on the daily chart, but the prevailing sentiment remains cautious.

Are Solara Active Pharma Sciences Ltd latest results good or bad?

The latest results for Solara Active Pharma Sciences Ltd are concerning, showing an 11.31% revenue growth to ₹349.00 crores but a significant net loss of ₹17.43 crores, indicating severe profitability issues despite top-line growth. Overall, the financial performance suggests a crisis in profitability that overshadows the revenue increase.

The latest results for Solara Active Pharma Sciences Ltd are concerning. While the company reported a significant revenue growth of 11.31% quarter-on-quarter, reaching ₹349.00 crores, it faced a dramatic decline in profitability. The net profit for Q3 FY26 was a loss of ₹17.43 crores, which is a staggering drop of 265.6% compared to the previous quarter and a 315.5% decline year-on-year. <BR><BR>Additionally, the operating margin fell sharply from 17.87% in the previous quarter to just 10.70%, and the profit after tax (PAT) margin turned negative at -4.99%, down from a positive 3.30% in Q2 FY26. These figures indicate that despite the top-line growth, the company is struggling with significant operational inefficiencies and cost pressures.<BR><BR>Overall, the financial performance suggests a crisis in profitability that overshadows the revenue growth, making the latest results appear quite bad for Solara Active Pharma.

Should I buy, sell or hold Solara Active Pharma Sciences Ltd?

Why is Solara Active Pharma Sciences Ltd falling/rising?

As of 07-Feb, Solara Active Pharma Sciences Ltd's stock price has declined to Rs 471.20, down 10.1%, due to poor recent performance, weak fundamentals, and decreasing institutional interest. The stock has underperformed its sector and benchmarks, reflecting a negative long-term growth outlook and challenges in servicing debt.

As of 07-Feb, Solara Active Pharma Sciences Ltd is experiencing a significant decline in its stock price, currently at Rs 471.20, which reflects a change of -52.95 (-10.1%). This downward movement is attributed to several factors highlighted in the recent performance data. <BR><BR>The stock has underperformed its sector by -9.3% today and has been on a consecutive decline for the last two days, resulting in a total drop of -12.2% during this period. Additionally, the stock touched an intraday low of Rs 462.3, indicating a high level of volatility with an intraday fluctuation of 7.95%. <BR><BR>In terms of longer-term performance, Solara Active has shown a negative return of -13.86% over the past year, while also underperforming against the Sensex and other benchmarks. The company's fundamentals reveal a weak long-term growth outlook, with a -13.96% compound annual growth rate (CAGR) in operating profits over the last five years and a high Debt to EBITDA ratio of 3.95 times, indicating challenges in servicing its debt.<BR><BR>Moreover, institutional investor participation has decreased, with a reduction of -0.64% in their stake over the previous quarter, suggesting a lack of confidence among more sophisticated investors. This decline in institutional interest, combined with the company's flat results in recent financial reports, including a negative profit before tax and low cash reserves, further contributes to the stock's falling price.<BR><BR>Overall, the combination of poor recent performance, weak fundamentals, and declining institutional interest are key factors driving the stock price of Solara Active Pharma Sciences Ltd downward.

Which are the latest news on Solara Active?